Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Operating Expenses (2022 - 2025)

CervoMed (CRVO) has disclosed Operating Expenses for 9 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 11.3% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.3 million through Dec 2025, up 15.51% year-over-year, with the annual reading at $32.3 million for FY2025, 15.51% up from the prior year.
  • Operating Expenses hit $8.3 million in Q4 2025 for CervoMed, roughly flat from $8.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $9.4 million in Q4 2024 to a low of $904054.0 in Q3 2022.
  • Historically, Operating Expenses has averaged $5.4 million across 4 years, with a median of $5.0 million in 2023.
  • Biggest YoY gain for Operating Expenses was 429.5% in 2023; the steepest drop was 37.77% in 2023.
  • Year by year, Operating Expenses stood at $938823.0 in 2022, then surged by 429.5% to $5.0 million in 2023, then surged by 89.15% to $9.4 million in 2024, then decreased by 11.3% to $8.3 million in 2025.
  • Business Quant data shows Operating Expenses for CRVO at $8.3 million in Q4 2025, $8.4 million in Q3 2025, and $8.4 million in Q2 2025.